Cargando…
The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity
N(6)-methyladenosine (m(6)A) is the most prevalent posttranscriptional modification on RNA. NK cells are the predominant innate lymphoid cells that mediate antiviral and antitumor immunity. However, whether and how m(6)A modifications affect NK cell immunity remain unknown. Here, we discover that YT...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225680/ https://www.ncbi.nlm.nih.gov/pubmed/34160549 http://dx.doi.org/10.1084/jem.20210279 |
_version_ | 1783712133080416256 |
---|---|
author | Ma, Shoubao Yan, Jiazhuo Barr, Tasha Zhang, Jianying Chen, Zhenhua Wang, Li-Shu Sun, Joseph C. Chen, Jianjun Caligiuri, Michael A. Yu, Jianhua |
author_facet | Ma, Shoubao Yan, Jiazhuo Barr, Tasha Zhang, Jianying Chen, Zhenhua Wang, Li-Shu Sun, Joseph C. Chen, Jianjun Caligiuri, Michael A. Yu, Jianhua |
author_sort | Ma, Shoubao |
collection | PubMed |
description | N(6)-methyladenosine (m(6)A) is the most prevalent posttranscriptional modification on RNA. NK cells are the predominant innate lymphoid cells that mediate antiviral and antitumor immunity. However, whether and how m(6)A modifications affect NK cell immunity remain unknown. Here, we discover that YTHDF2, a well-known m(6)A reader, is upregulated in NK cells upon activation by cytokines, tumors, and cytomegalovirus infection. Ythdf2 deficiency in NK cells impairs NK cell antitumor and antiviral activity in vivo. YTHDF2 maintains NK cell homeostasis and terminal maturation, correlating with modulating NK cell trafficking and regulating Eomes, respectively. YTHDF2 promotes NK cell effector function and is required for IL-15–mediated NK cell survival and proliferation by forming a STAT5–YTHDF2 positive feedback loop. Transcriptome-wide screening identifies Tardbp to be involved in cell proliferation or survival as a YTHDF2-binding target in NK cells. Collectively, we elucidate the biological roles of m(6)A modifications in NK cells and highlight a new direction to harness NK cell antitumor immunity. |
format | Online Article Text |
id | pubmed-8225680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-82256802022-02-02 The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity Ma, Shoubao Yan, Jiazhuo Barr, Tasha Zhang, Jianying Chen, Zhenhua Wang, Li-Shu Sun, Joseph C. Chen, Jianjun Caligiuri, Michael A. Yu, Jianhua J Exp Med Article N(6)-methyladenosine (m(6)A) is the most prevalent posttranscriptional modification on RNA. NK cells are the predominant innate lymphoid cells that mediate antiviral and antitumor immunity. However, whether and how m(6)A modifications affect NK cell immunity remain unknown. Here, we discover that YTHDF2, a well-known m(6)A reader, is upregulated in NK cells upon activation by cytokines, tumors, and cytomegalovirus infection. Ythdf2 deficiency in NK cells impairs NK cell antitumor and antiviral activity in vivo. YTHDF2 maintains NK cell homeostasis and terminal maturation, correlating with modulating NK cell trafficking and regulating Eomes, respectively. YTHDF2 promotes NK cell effector function and is required for IL-15–mediated NK cell survival and proliferation by forming a STAT5–YTHDF2 positive feedback loop. Transcriptome-wide screening identifies Tardbp to be involved in cell proliferation or survival as a YTHDF2-binding target in NK cells. Collectively, we elucidate the biological roles of m(6)A modifications in NK cells and highlight a new direction to harness NK cell antitumor immunity. Rockefeller University Press 2021-06-23 /pmc/articles/PMC8225680/ /pubmed/34160549 http://dx.doi.org/10.1084/jem.20210279 Text en © 2021 Ma et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Article Ma, Shoubao Yan, Jiazhuo Barr, Tasha Zhang, Jianying Chen, Zhenhua Wang, Li-Shu Sun, Joseph C. Chen, Jianjun Caligiuri, Michael A. Yu, Jianhua The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity |
title | The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity |
title_full | The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity |
title_fullStr | The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity |
title_full_unstemmed | The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity |
title_short | The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity |
title_sort | rna m(6)a reader ythdf2 controls nk cell antitumor and antiviral immunity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225680/ https://www.ncbi.nlm.nih.gov/pubmed/34160549 http://dx.doi.org/10.1084/jem.20210279 |
work_keys_str_mv | AT mashoubao thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT yanjiazhuo thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT barrtasha thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT zhangjianying thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT chenzhenhua thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT wanglishu thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT sunjosephc thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT chenjianjun thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT caligiurimichaela thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT yujianhua thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT mashoubao rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT yanjiazhuo rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT barrtasha rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT zhangjianying rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT chenzhenhua rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT wanglishu rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT sunjosephc rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT chenjianjun rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT caligiurimichaela rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity AT yujianhua rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity |